CLAIMS

1. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment or prevention of diarrhea and/or constipation in a subject, wherein the bacterial strain is able to convert H_2/CO_2 to acetate.

2. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment or prevention of diarrhea and/or constipation in a subject.

3. The use of claim 1 or claim 2, wherein the diarrhea and/or constipation is associated with IBS and/or an inflammatory disease of the intestine, preferably wherein the inflammatory disease is of the small intestine, colon or rectum.

4. The use of any one of claims 1-3, wherein the diarrhea and/or constipation is associated with IBS, Crohn's disease or ulcerative colitis or wherein the subject is diagnosed with IBS, Crohn's disease or ulcerative colitis.

5. The use of any preceding claim, wherein the medicament is for the treatment of diarrhea and wherein the subject has diarrhea without constipation.

6. The use of any one of claims 1-4, wherein the medicament is for the treatment of constipation and wherein the subject has constipation without diarrhea.

7. The use of any preceding claim, wherein the subject additionally has abdominal pain and/or bloating.

8. The use of any preceding claim, wherein the subject has an increased level of hydrogen in their breath relative to a healthy subject.

9. The use of any preceding claim, wherein the treatment or prevention further comprises reducing the hydrogen level in the breath of the subject.

10. The use of any preceding claim, wherein the treatment or prevention further comprises monitoring the hydrogen level in the subject's breath during and/or following the

treatment or prevention and thereby assessing the likely effectiveness of treatment or prevention.

11. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5 in the manufacture of a medicament for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in the treatment or prevention of diarrhea, wherein the bacterial strain is able to convert H_2/CO_2 to acetate.

12. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 in the manufacture of a medicament for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in the treatment or prevention of diarrhea.

13. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment or prevention of diarrhea associated with *Enterobacteriaceae* infection, wherein the bacterial strain is able to convert H_2/CO_2 to acetate.

14. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment or prevention of diarrhea associated with *Enterobacteriaceae* infection.

15. The use of any one of claims 11-14, wherein the *Enterobacteriaceae* is E. coli.

16. The use of any preceding claim, wherein the bacterial strain is of *Blautia hydrogenotrophica*.

17. The use of any of claims 1-15, wherein the bacterial strain is of *Blautia stercoris* or *Blautia wexlerae*.

18. The use of any one of claims 1-15, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia hydrogenotrophica, Blautia stercoris* or *Blautia wexlerae*.

19. The use of claim 16, wherein the bacterial strain has a 16s rRNA sequence that is at least

97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5 or which has the 16s rRNA sequence of SEQ ID NO:5.

20. The use of claim 1 or claim 2, wherein the composition comprises a bacterial strain of the species *Blautia hydrogenotrophica, Blautia stercoris* or *Blautia wexlerae*, and wherein the subject is diagnosed with IBS.

21. The use of any preceding claim, wherein the medicament is to be administered orally and/or wherein the medicament comprises one or more pharmaceutically acceptable excipients or carriers.

22. The use of any preceding claim, wherein the bacterial strain is lyophilised and/or viable.

23. The use of any preceding claim, wherein the composition comprises a single bacterial strain having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, wherein the bacterial strain is able to convert H_2/CO_2 to acetate or wherein the composition comprises a single bacterial strain having a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5.

24. The use of any one of claims 1-22, wherein the composition comprises a bacterial strain having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, wherein the bacterial strain is able to convert H_2/CO_2 to acetate as part of a microbial consortium or the composition comprises a bacterial strain having a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 as part of a microbial consortium.

25. The use of any preceding claim, wherein the medicament is a food product or a vaccine composition.